GSK
707 hedge funds and large institutions have $8.54B invested in GSK in 2015 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 261 increasing their positions, 265 reducing their positions, and 51 closing their positions.
58% more call options, than puts
Call options by funds: $182M | Put options by funds: $115M
0.18% less ownership
Funds ownership: 3.84% → 3.66% (-0.18%)
2% less repeat investments, than reductions
Existing positions increased: 261 | Existing positions reduced: 265
2% less funds holding
Funds holding: 721 → 707 (-14)
12% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 51
12% less capital invested
Capital invested by funds: $9.73B → $8.54B (-$1.19B)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$196M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$93.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$84.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$76.6M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$54.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$511M |
| 2 |
D.E. Shaw & Co
New York
|
-$81.2M |
| 3 |
Renaissance Technologies
New York
|
-$75.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$71.2M |
| 5 |
Barclays
London,
United Kingdom
|
-$39.2M |
GSK Hedge Fund Activity: Q3 2015 in Review
707 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2015, worth a combined $8.54B — down 12% from $9.73B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of GSK and 45 opened new positions — a net loss of 6 holders — while 265 trimmed existing stakes and 261 added.
The largest buyer was JP Morgan Chase, adding an estimated $196M. The largest seller was Dodge & Cox, cutting an estimated $511M.
- 707 institutional investors held GSK (GSK) as of Q3 2015, down from 721 in Q2 2015.
- Funds reported $8.54B of GSK stock for Q3 2015, down 12% quarter-over-quarter.
- 45 funds opened new GSK positions in Q3 2015 and 51 closed out, a net change of -6 holders.
- The largest GSK buyer in Q3 2015 was JP Morgan Chase, an estimated $196M added.
- The largest GSK seller in Q3 2015 was Dodge & Cox, an estimated $511M sold.
Based on aggregated 13F filings for Q3 2015.